The Role of Incumbent Firms and Universities as Drivers of Innovation: Evidence from the Comparison of the Markets for Anti-Cancer and AIDS-Treatment Drugs

M. Lourdes Sosa
Strategic and International Management
London Business School
London NW1 4SA, UK

e-mail: lsosa@london.edu
The Role of Incumbent Firms and Universities as Drivers of Innovation: Evidence from the Comparison of the Markets for Anti-Cancer and AIDS-Treatment Drugs

M. Lourdes Sosa
Strategic and International Management, London Business School, London NW1 4SA, UK, lsosa@london.edu

In this paper, I compare the dynamics of two different markets within the pharmaceutical industry: anti-cancer and AIDS-treatment drugs. The anti-cancer drug market was born in 1949 and had been in operation for decades prior to 1983, when the biotechnology revolution first disrupted it. In contrast, the market for AIDS-treatment drugs was born around 1985, during the biotechnology revolution. This implies not only that the markets differ significantly in age but that incumbents with respect to the biotechnology revolution can only be found in the former market. Based on field interviews, data on patented molecules from the Derwent World Patent Index collection 1994-2004, and data on drugs entering clinical trials from the Pharmaprojects database 1989-2004, I examine the differences in innovative output (measured in drug molecules per firm) among firms competing in each market. Preliminary results indicate that the average productivity is higher in the anti-cancer drug market than in the market for AIDS-treatment drugs. I explore two main mechanisms behind these results: the presence of incumbent firms (in the anti-cancer drug market but not the AIDS-treatment drug market), and the involvement of universities in both markets. Although this draft documents only the motivation and methodology behind this paper, the final objective of the project is to explore implications for the operation of research-intensive markets, and the role that large incumbents and universities play in shaping the dynamics of innovation.

Key words: university-industry collaboration; technological change; biotechnology; pharmaceuticals

1. Introduction

At least as far back as Schumpeter (1934, 1950), scholars have been interested in the transition of markets through technological discontinuities. Attention has been focused on the fate of incumbent firms, as dif-
fert factors determine whether their innovation ability decreases when faced with a new technological regime, and whether in spite of that loss of innovation ability, these firms get to retain significant market share as the disruption subsides (see Chesbrough, 2001, for a review). In contrast, recent research has centered on the dynamics surrounding the birth of markets, settings that therefore have no incumbents. Such research has been particularly fruitful in furthering our understanding of the differences in innovative ability between entrants to a market that have a pre-history (i.e., diversifying entrants) and those that do not (i.e., de novo firms). Studies in this recent tradition have spanned medical devices (Mitchell, 1994), automobiles (Carroll et al., 1996), and television sets (Klepper and Simons, 2000).

In light of studies in both traditions mentioned above, contrasting inferences have been made about the impact of established firms, either incumbents or diversifying firms (i.e., entrants with a pre-history), on total market-level innovative output. On the one hand, in creative destruction incumbents have been found to lose productivity in the research and development (R&D) of products under the new technological regime (Henderson, 1993), even if they do not ultimately lose the market (Tripsas, 1997). Therefore, the suspicion is that these firms do not easily cope with technological discontinuities, and in the presence of barriers to entry and exit, they slow down the innovative progress of the market as it transitions through the discontinuity. On the other hand, in studies where the technological discontinuity marks the birth of the market, diversifying firms have been found to outperform de novo firms (i.e., newly born firms) in several dimensions, including survival (e.g., Mitchell, 1994; Carroll et al., 1996) and new product introductions (e.g., Methe, Swaminathan, and Mitchell, 1996). Therefore, it seems easy to infer that these firms indeed stimulate the innovative progress of the market.

Nonetheless, it remains an open question whether the contrasting roles that established firms can have on the innovative progress of a market are a result of the research design employed and the unavailability of fine-grained datasets. Indeed, recent creative destruction research has found that once entrants are separated into diversifying and de novo firms as well, the difference between the innovative performance of the two firm categories with a pre-history, namely incumbents and diversifying entrants, is not signifi-
Sosa: The Role of Incumbent Firms and Universities as Drivers of Innovation
Revised April 15th, 2008

cant, and that the main gap is marked between established and de novo firms (Sosa, 2005, 2006). Therefore, the explanatory variable for the different findings of incumbents and diversifying entrants in transitioning vs. emerging markets could be differences in market characteristics.

In this study, I set out to compare two markets that constitute an ideal matched pair due precisely to their differences and similarities. On the one hand, these markets differ in the point in their life cycles at which the technological discontinuity is impacting them (a transition after decades of a previous technological regime for one and the birth for the other). This characteristic allows me to contrast a market with incumbent firms in transition (the former case) versus a market without incumbents (the latter case). On the other hand, these markets are similar in a number of key dimensions: both include diversifying and de novo entrants; both are among the most science-intensive markets within the pharmaceutical industry; both are facing the same technological discontinuity, that is, the biotechnology revolution; both have low price sensitivity and are far from satiation in the areas of efficacy and safety that consumers value; and both have involved a significant amount of university research in the history of their past and recent progress.

Beyond the matched pair that these particular empirical settings represent, I incorporate in this study a unique fine-grained level of measurement of innovation. In order to further understand the innovative output of these firm categories under contrasting market structures, I measure innovative output at three different points of the R&D process of a firm in this industry: the generation of patented drug molecules; the entry of some of those molecules into clinical trials; and the approval of some of those molecules after successful completion of clinical trials.

In preliminary results, I find that the average innovative output per firm is higher in the anti-cancer drug market than in the market for AIDS-treatment drugs only for early-stage research. After that, the effect is reversed: the market for AIDS-treatment drugs exhibits higher average innovative output per firm when measured at the entry of clinical trials and at approval for market launch. I propose to explore as possible mechanisms behind these results the presence of incumbent firms (in the anti-cancer drug market but not
the AIDS-treatment drug market), and the differential involvement of universities in both markets. Furthermore, I find that the *difference* among firm categories is greater in earlier stages of R&D. This is in part due to differences across firm categories in the ability to select which molecules to introduce in the next stage. However, the greater cross-firm category difference in early stages of R&D is also partly due to the expansion of the sample in earlier steps (where an increasing number of small firms, both diversifying and de novo, is captured in the dataset, many with treatments that would not enter clinical trials in the first place).

I close with a discussion of the implications of these findings for the operation of research-intensive markets, and for our understanding of the role that established firms, both incumbent firms and diversifying entrants, play in shaping the dynamics of innovation.

2. Empirical Setting

In order to analyze the contribution that incumbent firms make to market dynamics, I present in this paper a comparison of two contrasting market structures. The first is the market for anti-cancer drugs, a market that was in place long before the biotechnology revolution first disrupted it in 1983 and that therefore has had a set of market incumbents transitioning into biotechnology. In contrast, the second market is the market for AIDS-treatment drugs, a market that was born during the biotechnology revolution and that therefore has no market incumbents. These two markets offer a reasonable match for a paired design because they coincide in several of their key dimensions. As described below, I conducted 40 interviews to aid in understanding the dynamics of these markets and of the pharmaceutical industry in general, and interviewees were consistent in describing these two markets as science-intensive, where the research of the application itself (i.e., the therapeutic category) is as complex and value-adding as any of the technological platforms used in drug discovery and development (see also Weinberg, 1996, for the case of the anti-cancer drug market, and Kanki and Essex, 2005, for the case of the AIDS-treatment drug market). Since prior research (Sosa, 2008) has identified this contrast as a key driver in the dynamics of innovation in the transition of drug development into the biotechnology revolution, avoiding variance in this charac-
Characteristic was of utmost importance. Furthermore, both markets have low price sensitivity in the major markets, and are far from satiation on the part of consumers in terms of efficacy and safety, the two main aspects of merit in most pharmaceuticals (for examples of exceptions to this feature within pharmaceuticals, see Christensen, 1996).

I offer next further details on the characteristics of each of these markets and their measures.

4.1. The Anti-Cancer Drug Market

Although this market has long been in existence, the technological regime preceding the biotechnology revolution, namely cytotoxic drug development (commonly referred to as “chemotherapy”), started in 1949 (Chabner and Roberts, 2005). I took the approval of the first anti-cancer drug influenced by biotechnology, Intron-A®, introduced in 1983, as the start of the biotechnology discontinuity. From 1983, the anti-cancer drug market begins its transition from cytotoxic agents (e.g., antineoplastic antibiotics, alkylating agents, etc.) to the radically new category termed targeted drugs (e.g., tyrosine kinase inhibitors, monoclonal antibodies, etc.). In order to analyze the dynamics of innovation in this market, it is important to characterize the transition in terms of the comparison of the technological regimes used in cytotoxic vs. targeted drug R&D. The first question is whether the difference between the technological paradigms is incremental or radical (Henderson and Clark, 1990).¹ A second though related question is whether the difference is competence-destroying to the resources and capabilities that market incumbents have mastered in the R&D operations within their standing value chains (Tushman and Anderson, 1986).²

Studies have shown that the transition from cytotoxic to targeted R&D in anti-cancer drugs has been a

¹ In the case of assembled products, a further characterization would be needed to identify whether only the components are changing (modular change) or only the architecture is changing (architectural change).

² I refer to the contrast between incremental vs. radical and competence-destroying vs. competence-enhancing as related because some of their categories could be superimposed: incremental changes are competence-enhancing, whereas modular, architectural and radical could be argued as all being competence-destroying to varying degrees.
radical and competence-destroying change to this market (Rang, 2006: 49),\(^3\) albeit only to the preclinical (i.e., drug discovery) phase of R&D. A description of a representative value chain in this market is shown in Figure 1, where drug discovery can be identified. The description of this technological change as radical and competence-destroying is consistent with the responses of interviewees in this study and with biotechnology’s impact at the industry level as described in prior literature (e.g., Henderson, Orsenigo, and Pisano, 1999; Rothaermel, 2001).

As mentioned above, it was important to select a pair of markets where consumers were far from satiation in the main dimensions of product merit. In the case of the anti-cancer drug market that implied that the change, although a radical shift in technologies and competence-destroying to incumbents’ value chain, should be “sustaining” in customer preferences (Christensen, 1997). According to data by the American Cancer Society (2000), at the start of the discontinuity (and indeed for the full period of observation in this study) the market was far from satiation in the levels of efficacy and safety, the main dimensions of merit considered in an anti-cancer drug. Indeed, the 5-year survival rate had changed from 50% in the years 1974-1976, to 51% in the years 1980-1982, to 59% in the years 1989-1995, a trend that proves the market in general was far from satiation, even though the difference in rates between 1974-1976 and 1989-1995 is statistically significant (p<0.05). Customer preferences were clearly the maxim-

\(^3\) Accounts of the development of targeted anti-cancer drugs also illustrate this point (e.g., Capdeville et al., 2002).
zation of efficacy and safety, with ample room for improvement in those dimensions by any firm in competition.

Anti-Cancer Drug Market-Specific Explanatory Variables

Anti-Cancer Drug Market Incumbents These firms must have been present in the market for cytotoxic anti-cancer drugs before the era of biotechnology, and they must have been venturing into targeted anti-cancer drugs in the years under examination.\(^4\) Since the era of chemotherapy (i.e., cytotoxic anti-cancer drugs) in cancer treatment started in the 1940s (Chabner and Roberts, 2005), most records are incomplete.\(^5\) I therefore triangulated three different sources to identify incumbent firms: the records available from the Federal Drug Administration (FDA) on all approved drugs;\(^6\) the records available on anti-cancer drugs in particular from the FDA’s Center for Drug Evaluation and Research (FDA-CDER);\(^7\) and the printed collection of the Physicians’ Desk Reference (PDR) drug directories for the years 1947-2005. I took the approval of the first anti-cancer drug influenced by biotechnology, Intron-A\(^®\) (a recombinant-DNA molecule) introduced in 1983, as the start of the era of targeted anti-cancer drugs. An incumbent therefore would be a firm that was present in the market before 1983 and that after 1983 had at least one targeted anti-cancer drug either in clinical trials or already launched. Firms that were in the market but left for a significant period of time and were returning because of the biotechnology revolution were not

\(^4\) This implied that I would select incumbents contingent on investment in the radically new technology (i.e., a subset of all incumbents). In the end, this restriction made no difference because all incumbents still in the market by 1983 had invested in the new technology. Furthermore, all incumbents invested in the new technology from the start of the revolution.

\(^5\) For example, FDA records for drug approval are incomplete before 1982, mainly because this was prior to the approval of the Drug Price Competition and Patent Term Restoration Act of 1984 [the Hatch-Waxman Act], which gave rise to today’s generics drug industry.

\(^6\) From Drugs@FDA available electronically at [http://www.accessdata.fda.gov/scripts/cder/drugsatfda/](http://www.accessdata.fda.gov/scripts/cder/drugsatfda/).

considered incumbents but diversifying entrants.\(^8\) I therefore further corroborated the presence of the firms around 1983 by requiring that at least one of the cytotoxic anti-cancer drugs for the firm in question still generated revenue after 1983. I estimated this through one of two different proxies: at least one of the cytotoxic anti-cancer drugs for the firm in question must have had revenues listed in the Med Ad News’ yearly report of *Top Prescription Drugs* in the period 1991-2002, or must have had a generic introduction after the generics industry took off in 1984.\(^9\)

**Anti-Cancer Drug Market Diversifying vs. De Novo Entrants**

The identification of these two categories was done through access to their corporate histories, culled mainly from their company websites. Firms that had a pre-history prior to their incursion into the anti-cancer drug market were classified as diversifying entrants, regardless of whether they continued their presence in markets other than anti-cancer drugs during their incursion into this market. I defined a “pre-history” strictly as a prior stream of revenue. Therefore, entrants that experimented with different therapeutic categories either in their laboratories or their mission statements were still classified as de novo entrants. In contrast, entrants that derived a revenue stream from any other business (e.g., medical devices or research services), were classified as diversifying entrants, even if the firm itself was rather young and small.

### 4.2. The Market for AIDS-Treatment Drugs

As mentioned above, in contrast to the anti-cancer drug market, the market for AIDS-treatment drugs was born during the biotechnology revolution. According to the USA Centers for Disease Control and Prevention (CDC, 2007), HIV (Human Immunodeficiency Virus) was first identified in the United States in 1981. Although the deadly disease was first described as a rare pneumonia, by December 1982 publica-

\(^8\) For example, Merck made two attempts to enter the anti-cancer drugs market with Nitrogen Mustards *Mustargen*\(^\text{®}\) and *Cosmegen*\(^\text{®}\) in the years 1949 and 1966, respectively, but was by 1983 long gone from the market. Neither product had significant sales by 1983. Cosmegen is even reported as unprofitable in Merck’s Annual Report in 1951. As Merck was attempting to enter the anti-cancer drugs market again, it is classified as a diversifying entrant.

\(^9\) I assume that only anti-cancer drugs with positive revenues will incite generic competition.
tions would refer to the disease as acquired immune deficiency syndrome (AIDS). Indeed, according to scientific accounts, although the virus responsible for the disease was a genetic relative of a known virus, it had been recently introduced to humans from a primate reservoir (Essex and Kanki, 1988). This particular characteristic makes the market for AIDS-treatment drugs a perfect contrasting market to the anti-cancer drug market: although demand for cancer treatment had existed long before the transition into biotechnology and in fact demand had existed long before supply started to become available, the market for AIDS-treatment drugs had neither supply nor demand prior to 1982. Interest in researching the application-side of R&D in the AIDS-treatment drug market grew rapidly as did the availability of public funding for this research (Kanki and Essex, 2005), and by 1984, the human immunodeficiency virus (HIV) was recognized as the etiologic agent that causes AIDS. As the application-side of the R&D of this market evolved, so did specific applications of technological platforms (e.g., polymerase chain reaction [PCR]). By 1985, for example, the first blood test to identify antibodies to the virus and hence diagnose the disease (namely, the ELISA test) was finally available (CDC, 2006).

**AIDS-Treatment Drug Market-Specific Explanatory Variables**

As mentioned above, this market itself had no pre-history, that is, the market had not existed in a prior technological regime. Indeed, the consumer need itself did not existed prior to 1981 since this specific disease is a recent genetic mutation transferred to humans from the animal world. This implies that there are no incumbent firms in this market, and that there are no contrasting technological regimes in the history of the market. The only market-specific explanatory variable, therefore, is the differentiation of diversifying and de novo entrants, and I describe this next.

**AIDS-Treatment Drug Market Diversifying vs. De Novo Entrants** The identification of these two categories was done through access to their corporate histories, culled mainly from their company websites. Firms that had a pre-history prior to their incursion into the anti-cancer drug market were classified as diversifying entrants, regardless of whether they continued their presence in markets other than anti-cancer drugs during their incursion into this market. I defined a “pre-history” strictly as a prior stream of
revenue. Therefore, entrants that experimented with different therapeutic categories either in their laboratories or their mission statements were still classified as de novo entrants. In contrast, entrants that derived a revenue stream from any other business (e.g., medical devices or research services), were classified as diversifying entrants, even if the firm itself was rather young and small.

4.3. Nonmarket-Specific Quantitative Measures

For the comparison of the two above-mentioned markets, I had to use a series of variables that are invariant with respect to the market in question. I describe these variables next.

**Dependent Variables**

*Number of Patented Drug Molecules* According to the value chain presented in Figure 1 above, a firm in the pharmaceutical industry, whether in anti-cancer or AIDS-treatment drug development, will generate many new drug molecules during the drug discovery stages, and patent them at different points though always prior to starting the transition towards clinical trials, since this transition implies disclosure. In order to measure this step, I used Thomson Scientific’s Derwent World Patent Index (DWPI) database. The DWPI database consists of innovation records, identified through the categorization of patents into predetermined classes (identified by a code) by a set of expert librarians. Patents are collected from the 40 largest jurisdictions, and the classification process includes the matching of patents containing the same idea to the same innovation record. Therefore, the unit of analysis is the innovation, and each record can be matched to one or several granted patents. Because the classes are defined by the librarians themselves, anti-cancer and AIDS-treatment drugs are defined, but other therapeutic classes are not. Furthermore, anti-cancer and AIDS-treatment drugs are defined starting only in 1994, so this measure can only be made in the window of 1994-2004. In the case of anti-cancer drugs, it was important to also differentiate between the two technological regimes. I therefore differentiated between standard chemotherapy (i.e., cytotoxic anti-cancer drugs) and biotech-based drug development (i.e., targeted anti-cancer drugs) through further use of the DWPI codes. In fieldwork, interviewees had described the different subclasses contained within cytotoxic vs. targeted drugs in anti-cancer research (e.g., interleukins and ty-
rosine kinase inhibitors among targeted drugs). Therefore, I identified all codes pointing to sub-classes of targeted anti-cancer drugs, to then aggregate to the technological regime.

**Number of Drug Molecules Introduced in Clinical Trials** Continuing along the value chain presented in Figure 1 above, after the generation of new drug molecules during the drug discovery stages, a sub-set of these drug molecules will enter clinical trials. In order to examine this transition, I collected data on all drugs that entered clinical trials for treatment of cancer and AIDS, as reported in PJB’s Pharmaprojects database. This database starts in 1989 and records all drugs launched into clinical trials worldwide along with their histories, as represented through press releases. In the case of anti-cancer drugs, I further differentiated between the old and new technology, namely cytotoxic and targeted anti-cancer drugs, through the dummy “targeted.” I again did this by measuring first two sub-classes of targeted drugs, in this case targeted small molecules and targeted large molecules, to then assess the full category of targeted drugs. The identification of targeted large-molecule anti-cancer drugs is reliably documented in the Pharmaprojects database. To identify targeted small molecules, I selected all small molecule drugs with mechanisms of action described in industry reports (Bear Sterns, 2002; Stephens Inc., 2002; UBS Warburg, 2001) and in interviews as targeted in anti-cancer drug R&D (in the end, mainly comprising angiogenesis and kinase inhibitors).

**Number of Drug Molecules Approved for Market Launch** At the end of the R&D process depicted in the value chain shown in Figure 1, a sub-set of drugs in clinical trials is granted approval to launch on the market (even though it remains discretionary to the firm how much later and through which channels to commercialize the innovation). I measured this through the full collection of Thomson Scientific’s Physicians’ Desk Reference (PDR) annual directory of approved drugs, 1947-2004. Although a full record of approved drugs can be requested from the FDA, for example, as mentioned in the definition of anti-cancer drug market incumbents, the information is often incomplete prior to 1984, the year when the Hatch-Waxman Act entered into effect. Hence, the use of the PDR collection granted further systematic cover-
In order to differentiate between cytotoxic and targeted anti-cancer drugs, I again used the information in the PDR collection to classify drugs into sub-classes of targeted drugs to then aggregate.

**Nonmarket-Specific Explanatory Variables**

*Public Research Organizations* In contrast to the firm categories I specified in each market, the classification of nonprofit organizations was not market-specific. I therefore distinguished only between private and public research with the dummy variable “public research,” which spanned all nonprofit organizational arrangements, including universities, government laboratories, and nongovernmental organizations.

5. **Introductory Descriptive Statistics**

In preliminary analyses, significant differences can be seen in the trends of innovative output both across the different stages of the R&D pipeline, but also in each stage across firm categories. Figure 2 below shows simply the contrast of approved drugs between the two markets in the history of their evolution. Although there is a marked fluctuation in the anti-cancer drug market around 1971, this is mostly due to a change in the accounting of pain medication as a cancer-only adjuvant in the *PDR* collection that served as information source.

![Figure 2: History of Available Drugs for Cancer and AIDS Treatment](image)
Table 1 presents the total number of drugs at each of the three stages in the R&D pipeline of both markets. The increase in the number of molecules in earlier stages (i.e., the comparison of the volume of patented molecules versus those entering clinical trials) is partly explained by the expanded coverage that the sample of firms based on patented drug molecules generates. Many firms from developing countries (e.g., Mexico, India, Tanzania) appear in this early-stage sample and do not appear in later stages.

<table>
<thead>
<tr>
<th></th>
<th>Patented Molecules</th>
<th>Drugs in Clinical Trials</th>
<th>Approved Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Cancer</td>
<td>55,242</td>
<td>6,851</td>
<td>307 (since 1949)</td>
</tr>
<tr>
<td>AIDS-Treatment</td>
<td>3,168</td>
<td>1,244</td>
<td>56</td>
</tr>
</tbody>
</table>

Figure 3 presents the gap in innovative output between the two markets as it widens over time, as measured at the first stage in this study, namely patented molecules in early-stage R&D.

Figure 3: Gap on Innovative Output between the Anti-Cancer and AIDS-Treatment Markets over Time, as Measured in Early-Stage R&D (Generation of Patented Drug Molecules)
Indeed, the gap in innovative output is sustained across the years in the period of observation, not only in terms of absolute volume of drugs but also in terms of per-firm productivity, as seen in Figure 4 below.

**Figure 4**: Persistent Gap between the Average Innovative Output of Firms in the Anti-Cancer and AIDS-Treatment Drug Markets, as measured in the Generation of Patented Molecules in Early-Stage R&D

6. Concluding Remarks

Although the analysis of the project outlined in this draft, to be presented at the Sloan Industry Studies conference 2008, is still under progress, initial descriptive statistics support the advantages that the unique paired-market design along with fine-grain measurement of R&D output, can offer to studies of the drivers of innovation.

**Acknowledgments**

I thank Zuzana Grygarova and Kate Parsons for meticulous research assistance.
References


Sosa: The Role of Incumbent Firms and Universities as Drivers of Innovation
Revised April 15th, 2008


